AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 19494795 — intervention group
Group type: EXPERIMENTAL
Intervention: NGX-4010 capsaicin patch (640 microg/cm2) applied for 90 minutes
Number of subjects: 173
Study 19494795 — intervention group
Group type: EXPERIMENTAL
Intervention: NGX-4010 capsaicin patch (640 microg/cm2) applied on feet
Number of subjects: 173
Study 19494795 — intervention group
Group type: EXPERIMENTAL
Intervention: NGX-4010 capsaicin patch (640 microg/cm2) with larger treatment areas
Number of subjects: 173
Study 17185118 — intervention group
Group type: COMPARATOR
Intervention: Lidocaine with epinephrine (36 mg lidocaine + 18 mug epinephrine)
Number of subjects: 48
Study 17185118 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine plus meperidine with epinephrine (36 mg lidocaine + 18 mug epinephrine + 36 mg meperidine + 18 mug epinephrine)
Number of subjects: 48
Study 15794456 — intervention group
Group type: COMPARATOR
Intervention: 5% carbamide peroxide professional custom tray system
Number of subjects: 43
Study 15794456 — intervention group
Group type: EXPERIMENTAL
Intervention: 18% carbamide peroxide paint-on gel
Number of subjects: 43
Study 15794456 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% hydrogen peroxide dentifrice with manganese gluconate activator
Number of subjects: 43
Study 14700480 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral bexarotene 300 mg/m2/day
Number of subjects: 54
Study 14700480 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral bexarotene 600 mg/m2/day
Number of subjects: 54
Study 14700480 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study 14700480 — intervention group
Group type: COMPARATOR
Intervention: Placebo (prior chemotherapy responders)
Number of subjects: 54
Study 14700480 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral bexarotene 300 mg/m2/day (prior chemotherapy responders)
Number of subjects: 54
Study 14700480 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral bexarotene 600 mg/m2/day (prior chemotherapy responders)
Number of subjects: 54
Study 9643407 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary surgery (total abdominal hysterectomy and bilateral salpingo-oophorectomy)
Number of subjects: 19
Study 9643407 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative adjuvant therapy (radiotherapy and/or systemic chemotherapy)
Number of subjects: 19
Study 7563044 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceived behavioral control (PBC)
Number of subjects: 0
Study 7563044 — intervention group
Group type: EXPERIMENTAL
Intervention: Low binge eaters
Number of subjects: 0
Study 7563044 — intervention group
Group type: EXPERIMENTAL
Intervention: High binge eaters
Number of subjects: 0
Study 7563044 — intervention group
Group type: EXPERIMENTAL
Intervention: Group attendance
Number of subjects: 0
Study 2789438 — intervention group
Group type: EXPERIMENTAL
Intervention: 15% polyvinylpyrrolidone (PVP) solution
Number of subjects: 123
Study 2789438 — intervention group
Group type: EXPERIMENTAL
Intervention: 20% polyvinylpyrrolidone (PVP) solution
Number of subjects: 123
Study 2789438 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 123
Study 2789438 — intervention group
Group type: EXPERIMENTAL
Intervention: PVP (both concentrations)
Number of subjects: 123
Study 269080 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine digluconate (0.1%)
Number of subjects: 0
Study 269080 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31796571 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Intensity Intermittent Exercise (HIIE)
Number of subjects: 12
Study 31796571 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-Intensity Exercise (MIE)
Number of subjects: 12
Study 31579003 — intervention group
Group type: EXPERIMENTAL
Intervention: Radium-223 added to abiraterone acetate and prednisone or prednisolone
Number of subjects: 0
Study 31579003 — intervention group
Group type: COMPARATOR
Intervention: Placebo added to abiraterone acetate and prednisone or prednisolone
Number of subjects: 0
Study 28339098 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy with concurrent cediranib and continued as maintenance
Number of subjects: 456
Study 28339098 — intervention group
Group type: COMPARATOR
Intervention: Standard chemotherapy only
Number of subjects: 456
Study 25666325 — intervention group
Group type: EXPERIMENTAL
Intervention: Right Ventricular Apical (RVA) pacing
Number of subjects: 145
Study 23865654 — intervention group
Group type: EXPERIMENTAL
Intervention: Estrogen therapy (ET)
Number of subjects: 18601
Study 23865654 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18601
Study 21060206 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythropoietin (EPO) administration
Number of subjects: 0
Study 21060206 — intervention group
Group type: COMPARATOR
Intervention: Control group (no EPO administration)
Number of subjects: 0
Study 18068905 — intervention group
Group type: EXPERIMENTAL
Intervention: Contingency management (CM)
Number of subjects: 116
Study 18068905 — intervention group
Group type: COMPARATOR
Intervention: Noncontingent control
Number of subjects: 116
Study 16604826 — intervention group
Group type: EXPERIMENTAL
Intervention: Letrozole (2.5 mg daily for 5 days)
Number of subjects: 106
Study 16604826 — intervention group
Group type: COMPARATOR
Intervention: Clomiphene citrate (100 mg daily for 5 days)
Number of subjects: 106
Study 16604826 — intervention group
Group type: EXPERIMENTAL
Intervention: Letrozole
Number of subjects: 106
Study 16604826 — intervention group
Group type: COMPARATOR
Intervention: Clomiphene citrate (CC)
Number of subjects: 106
Study 12591062 — intervention group
Group type: EXPERIMENTAL
Intervention: Neomycin
Number of subjects: 111
Study 12591062 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 111
Study 10748791 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-blocker treatment (Bisoprolol)
Number of subjects: 0
Study 2123239 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate treatment with penicillin V (10-day course starting at diagnosis)
Number of subjects: 113
Study 2123239 — intervention group
Group type: COMPARATOR
Intervention: Delayed treatment with penicillin V (10-day course starting after 48 hours)
Number of subjects: 113
Study 6104858 — intervention group
Group type: EXPERIMENTAL
Intervention: tiapride (300 mg daily for 3-4 weeks)
Number of subjects: 30
Study 6104858 — intervention group
Group type: COMPARATOR
Intervention: floctafenine (200 mg daily for 3-4 weeks)
Number of subjects: 30
Study 30755154 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-intensity aerobic and resistance exercise
Number of subjects: 20
Study 30755154 — intervention group
Group type: COMPARATOR
Intervention: Non-exercising group (control)
Number of subjects: 20
Study 28174175 — intervention group
Group type: EXPERIMENTAL
Intervention: Online ECG monitoring education program and strategies to implement and sustain change in practice
Number of subjects: 3013
Study 28174175 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 3013
Study 27060951 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness Training (MT)
Number of subjects: 14
Study 27060951 — intervention group
Group type: COMPARATOR
Intervention: Psychoeducation (PE)
Number of subjects: 14
Study 25823177 — intervention group
Group type: EXPERIMENTAL
Intervention: Intralesional triamcinolone acetonide alone (Group A)
Number of subjects: 150
Study 25823177 — intervention group
Group type: COMPARATOR
Intervention: Triamcinolone acetonide + 5-fluorouracil (Group B)
Number of subjects: 150
Study 21594650 — intervention group
Group type: EXPERIMENTAL
Intervention: darapladib
Number of subjects: 330
Study 21594650 — intervention group
Group type: EXPERIMENTAL
Intervention: statin use
Number of subjects: 330
Study 21594650 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 330
Study 20638874 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin infusion (50 mg IV during surgery) and oral melatonin (10 mg for 3 nights post-surgery)
Number of subjects: 50
Study 20638874 — intervention group
Group type: COMPARATOR
Intervention: Placebo infusion and oral placebo
Number of subjects: 50
Study 20638874 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin treatment
Number of subjects: 50
Study 20638874 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 50
Study 18157888 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 48
Study 18157888 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin
Number of subjects: 48
Study 18157888 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 15746463 — intervention group
Group type: EXPERIMENTAL
Intervention: Cilostazol 200 mg per day
Number of subjects: 135
Study 15746463 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 135
Study 15259400 — intervention group
Group type: EXPERIMENTAL
Intervention: Prospective memory training (PM training) consisting of errorless learning and spaced retrieval techniques taught in six sessions in subjects' homes.
Number of subjects: 0
Study 15259400 — intervention group
Group type: COMPARATOR
Intervention: Untrained AD controls
Number of subjects: 0
Study 10480207 — intervention group
Group type: EXPERIMENTAL
Intervention: Vigabatrin (GVG) therapy
Number of subjects: 24
Study 10480207 — intervention group
Group type: COMPARATOR
Intervention: Control group (no GVG)
Number of subjects: 24
Study 7832130 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous transluminal coronary angioplasty (PTCA)
Number of subjects: 207
Study 7832130 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up after PTCA
Number of subjects: 207
Study 7832130 — intervention group
Group type: COMPARATOR
Intervention: Comparison to CABG
Number of subjects: 207
Study 2469451 — intervention group
Group type: EXPERIMENTAL
Intervention: Moclobemide (100, 200, and 300 mg)
Number of subjects: 8
Study 2469451 — intervention group
Group type: COMPARATOR
Intervention: Deprenyl (10 mg)
Number of subjects: 8
Study 6165144 — intervention group
Group type: EXPERIMENTAL
Intervention: Midodrine
Number of subjects: 0
Study 6165144 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31942627 — intervention group
Group type: EXPERIMENTAL
Intervention: Darunavir/ritonavir 800/100 mg q24h with rifampicin, escalated to darunavir/ritonavir 1600/200 mg q24h and 800/100 mg q12h.
Number of subjects: 28
Study 31942627 — intervention group
Group type: EXPERIMENTAL
Intervention: Darunavir/ritonavir adjusted doses with rifampicin.
Number of subjects: 28
Study 31942627 — intervention group
Group type: COMPARATOR
Intervention: Not applicable (control group not explicitly mentioned).
Number of subjects: 28
Study 31399138 — intervention group
Group type: EXPERIMENTAL
Intervention: Booklet self-help program with coaching (6 lessons over 8 weeks, 1-2 hours per week)
Number of subjects: 200
Study 31399138 — intervention group
Group type: COMPARATOR
Intervention: Attention-only control condition
Number of subjects: 200
Study 28973683 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D (20,000 IU per week)
Number of subjects: 76
Study 28973683 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 76
Study 26620289 — intervention group
Group type: EXPERIMENTAL
Intervention: Housing First with Assertive Community Treatment (ACT)
Number of subjects: 950
Study 25432250 — intervention group
Group type: EXPERIMENTAL
Intervention: Indirect bonding procedure
Number of subjects: 64
Study 25432250 — intervention group
Group type: COMPARATOR
Intervention: Direct bonding procedure
Number of subjects: 64
Study 22572824 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-acting octreotide (Sandostatin LAR®) depot 30 mg intramuscularly every month
Number of subjects: 33
Study 22572824 — intervention group
Group type: COMPARATOR
Intervention: 0.9% sodium chloride (control)
Number of subjects: 33
Study 22572824 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-acting octreotide
Number of subjects: 33
Study 20500927 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mg quercetin/d
Number of subjects: 120
Study 20500927 — intervention group
Group type: EXPERIMENTAL
Intervention: 1000 mg quercetin/d
Number of subjects: 120
Study 20500927 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 17971108 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicorette polacrilex gum (6 mg)
Number of subjects: 28
Study 17971108 — intervention group
Group type: COMPARATOR
Intervention: Placebo gum
Number of subjects: 28
Study 15655036 — intervention group
Group type: EXPERIMENTAL
Intervention: Evidence-based decision-making framework for obesity prevention
Number of subjects: 0
Study 12433727 — intervention group
Group type: EXPERIMENTAL
Intervention: Selenium-enriched yeast supplementation (247 micro g selenium/day)
Number of subjects: 36
Study 12433727 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 10527445 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic cholecystectomy (LC)
Number of subjects: 22
Study 10527445 — intervention group
Group type: COMPARATOR
Intervention: Minilaparotomy cholecystectomy (MC)
Number of subjects: 22
Study 10527445 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 22
Study 7669482 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluparoxan (twice-daily for 5 1/2 days, 11 doses)
Number of subjects: 16
Study 7669482 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 7669482 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine (200 micrograms infused intravenously over 5 min)
Number of subjects: 16
Study 2161038 — intervention group
Group type: EXPERIMENTAL
Intervention: WI79-9 vaccine (10^7.3 plaque-forming units/dose, 2 doses, 28 days apart)
Number of subjects: 77
Study 2161038 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 77
Study 2161038 — intervention group
Group type: EXPERIMENTAL
Intervention: WI79-9 vaccine
Number of subjects: 77
Study 6856679 — intervention group
Group type: EXPERIMENTAL
Intervention: Lateral method for an obtuse angle
Number of subjects: 40
Study 6856679 — intervention group
Group type: EXPERIMENTAL
Intervention: Lateral method for an acute angle
Number of subjects: 40
Study 6856679 — intervention group
Group type: EXPERIMENTAL
Intervention: Over-the-joint method for an obtuse angle
Number of subjects: 40
Study 6856679 — intervention group
Group type: EXPERIMENTAL
Intervention: Over-the-joint method for an acute angle
Number of subjects: 40
Study 31658903 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervical carotid atherosclerosis
Number of subjects: 666
Study 31658903 — intervention group
Group type: COMPARATOR
Intervention: Cardioembolic stroke
Number of subjects: 666
Study 28961977 — intervention group
Group type: EXPERIMENTAL
Intervention: cART initiation
Number of subjects: 84
Study 26421702 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous 50 μg bolus of phenylephrine (Group P)
Number of subjects: 40
Study 26421702 — intervention group
Group type: COMPARATOR
Intervention: Saline (Group S)
Number of subjects: 40
Study 24300437 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental intervention to promote breastfeeding
Number of subjects: 13879
Study 24300437 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental group
Number of subjects: 13879
Study 24300437 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 13879
Study 22317042 — intervention group
Group type: EXPERIMENTAL
Intervention: Free navigation style
Number of subjects: 0
Study 22317042 — intervention group
Group type: COMPARATOR
Intervention: Restricted navigation style
Number of subjects: 0
Study 22317042 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulator sickness measurement
Number of subjects: 0
Study 22317042 — intervention group
Group type: EXPERIMENTAL
Intervention: Balancing tests
Number of subjects: 0
Study 19713403 — intervention group
Group type: EXPERIMENTAL
Intervention: Humidification therapy techniques (specific techniques not detailed in the abstract)
Number of subjects: 8
Study 19713403 — intervention group
Group type: EXPERIMENTAL
Intervention: Preferred technology (specific technology not detailed in the abstract)
Number of subjects: 8
Study 17823673 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonic system with polishing fluid containing hydroxylapatite granules
Number of subjects: 30
Study 17823673 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonic system only
Number of subjects: 30
Study 17823673 — intervention group
Group type: EXPERIMENTAL
Intervention: Medium-hard toothbrush with polishing fluid
Number of subjects: 30
Study 17823673 — intervention group
Group type: EXPERIMENTAL
Intervention: Toothbrush only
Number of subjects: 30
Study 17823673 — intervention group
Group type: COMPARATOR
Intervention: Untreated control group
Number of subjects: 30
Study 14723988 — intervention group
Group type: EXPERIMENTAL
Intervention: Dihydroartemisinin-trimethoprim-piperaquine (DHA-TP)
Number of subjects: 114
Study 14723988 — intervention group
Group type: COMPARATOR
Intervention: Artesunate-mefloquine (A3M)
Number of subjects: 114
Study 14723988 — intervention group
Group type: EXPERIMENTAL
Intervention: Dihydroartemisinin-piperaquine
Number of subjects: 114
Study 14723988 — intervention group
Group type: EXPERIMENTAL
Intervention: Dihydroartemisinin-piperaquine and DHA-TP
Number of subjects: 114
Study 11535941 — intervention group
Group type: EXPERIMENTAL
Intervention: Clobazam and tramadol administration
Number of subjects: 0
Study 11535941 — intervention group
Group type: COMPARATOR
Intervention: Experimental stress conditions (isolation, food and sleep deprivation, extreme temperatures)
Number of subjects: 0
Study 9568465 — intervention group
Group type: COMPARATOR
Intervention: Normal control subjects
Number of subjects: 17
Study 9568465 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with Billroth II gastrojejunostomy
Number of subjects: 17
Study 7817819 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) treatment at a dosage of 0.2 IU/kg/day for 3 days
Number of subjects: 30
Study 7817819 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) treatment
Number of subjects: 30
Study 3265378 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulbactam/ampicillin 2g plus sulbactam 1g 3 times a day
Number of subjects: 23
Study 3265378 — intervention group
Group type: COMPARATOR
Intervention: Cefotaxime 2g 3 times a day
Number of subjects: 23
Study 29980162 — intervention group
Group type: EXPERIMENTAL
Intervention: Home based electrostimulation therapy (EST) with amplitude modulated current (base frequency of 4000 Hz, frequency band of 100–250 Hz) over 2 weeks adjuvant to a concurrent sinusitis therapy with topical corticosteroids
Number of subjects: 16
Study 28118308 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-pressure continuous BFR
Number of subjects: 17
Study 28118308 — intervention group
Group type: EXPERIMENTAL
Intervention: High-pressure intermittent BFR
Number of subjects: 17
Study 28118308 — intervention group
Group type: COMPARATOR
Intervention: Heavy-load resistance exercise (80% 1RM)
Number of subjects: 17
Study 28118308 — intervention group
Group type: COMPARATOR
Intervention: Light-load resistance exercise (20% 1RM)
Number of subjects: 17
Study 26363574 — intervention group
Group type: EXPERIMENTAL
Intervention: Trapeziectomy with ligament reconstruction using a bone tunnel (Burton‐Pellegrini)
Number of subjects: 79
Study 26363574 — intervention group
Group type: COMPARATOR
Intervention: Tendon sling arthroplasty (Weilby)
Number of subjects: 79
Study 23212807 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose risperidone (1.25 mg/day for 20 to <45 kg; 1.75 mg/day for >45 kg)
Number of subjects: 96
Study 23212807 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose risperidone (0.125 mg/day for 20 to <45 kg; 0.175 mg/day for >45 kg)
Number of subjects: 96
Study 23212807 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 96
Study 23212807 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose risperidone
Number of subjects: 96
Study 23212807 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose risperidone
Number of subjects: 96
Study 21178989 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 mg sustained-release dextroamphetamine (d-AMP)
Number of subjects: 60
Study 21178989 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 18341945 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of a recognized risk assessment chart
Number of subjects: 200
Study 18341945 — intervention group
Group type: COMPARATOR
Intervention: No use of a recognized risk assessment chart
Number of subjects: 200
Study 18341945 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of a patient information sheet
Number of subjects: 200
Study 18341945 — intervention group
Group type: EXPERIMENTAL
Intervention: Previous peripheral angioplasty
Number of subjects: 200
Study 15515137 — intervention group
Group type: EXPERIMENTAL
Intervention: Seemingly unrelated regression equations with inverse probability weighting for parameter estimation
Number of subjects: 0
Study 15515137 — intervention group
Group type: EXPERIMENTAL
Intervention: Survival time
Number of subjects: 0
Study 15515137 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality-adjusted survival time
Number of subjects: 0
Study 12713240 — intervention group
Group type: EXPERIMENTAL
Intervention: Foreknowledge of the target's color
Number of subjects: 0
Study 12713240 — intervention group
Group type: EXPERIMENTAL
Intervention: Preview presentations with target sharing color with a single colored set of previewed letters
Number of subjects: 0
Study 12713240 — intervention group
Group type: EXPERIMENTAL
Intervention: Removing similarity across displays
Number of subjects: 0
Study 12713240 — intervention group
Group type: EXPERIMENTAL
Intervention: Assessment of probability effects of target color
Number of subjects: 0
Study 12713240 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhibitory carryover from a preview color group
Number of subjects: 0
Study 12713240 — intervention group
Group type: EXPERIMENTAL
Intervention: Anticipatory set for a known target color
Number of subjects: 0
Study 10320186 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane (0.2% or 0.4% end-tidal) + Nitrous oxide (30% end-tidal)
Number of subjects: 20
Study 10320186 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane (0.2% or 0.4% end-tidal)
Number of subjects: 20
Study 10320186 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrous oxide (30% end-tidal)
Number of subjects: 20
Study 10320186 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrous oxide (30% end-tidal) + Sevoflurane (0.2% or 0.4% end-tidal)
Number of subjects: 20